

Freedom of Information request 493-20

Request

1. How many patients were treated (for any condition) in the latest 6-month period with the following drugs:
 - Juluca (rilpivirine/dolutegravir)
 - Dovato (lamivudine/dolutegravir)
 - Triumeq (abacavir/lamivudine/dolutegravir)
 - Tivicay (dolutegravir)
 - Isentress (raltegravir)
 - Biktarvy (TAF/emtricitabine/bictegravir)
 - Genvoya (TAF/emtricitabine/elvitegravir/cobisistat)
 - Symtuza (TAF/emtricitabine/darunavir/cobisistat)
 - Odefsey (TAF/emtricitabine/rilpivirine)
 - Descovy (TAF/emtricitabine)
 - Truvada or generic TDF/emtricitabine

2. How many patients received any antiretroviral (ART) therapy for HIV treatment (excluding pre-exposure prophylaxis):
 - a. for the latest 6-month period
 - b. for the 6 months from July-December 2019

3. How many patients were treated in the latest 6-months period with Truvada or generic TDF/emtricitabine for:
 - a. HIV treatment
 - b. Pre-exposure prophylaxis (PrEP)

4. How many packs of Truvada or generic TDF/emtricitabine were dispensed in latest 6-month period for:
 - a. HIV treatment
 - b. Pre-exposure prophylaxis (PrEP)

Response

1. The table below details the number of patients treated in the last 6 months:

Drug	Patients
Juluca (rilpivirine/dolutegravir)	<5
Dovato (lamivudine/dolutegravir)	13
Triumeq (abacavir/lamivudine/dolutegravir)	20
Tivicay (dolutegravir)	<5
Isentress (raltegravir)	9
Biktarvy (TAF/emtricitabine/bictegravir)	14
Genvoya (TAF/emtricitabine/elvitegravir/cobisistat)	<5
Symtuza (TAF/emtricitabine/darunavir/cobisistat)	<5
Odefsey (TAF/emtricitabine/rilpivirine)	<5
Descovy (TAF/emtricitabine)	<5
Truvada or generic TDF/emtricitabine	10

2.
 - a. 49 patients received ART therapy for HIV treatment in the last six months.
 - b. 43 patients received ART therapy for HIV treatment between July and December 2019.
3.
 - a. 13 patients were treated with Truvada or generic TDF/emtricitabine for HIV treatment in the last six months.
 - b. 17 patients were treated with Truvada or generic TDF/emtricitabine for Pre-exposure prophylaxis in the last six months.
4.
 - a. 70 boxes were prescribed for HIV treatment.
 - b. 62 boxes were prescribed for pre-exposure prophylaxis.

If you are not satisfied with the way your request has been handled or the decision given, you may ask NHS Borders to review its actions and the decision. If you would like to request a review please apply in writing to, Freedom of Information Review, NHS Borders, Room 2EC3, Education Centre, Borders General Hospital, Melrose, TD6 9BS or foi.enquiries@borders.scot.nhs.uk.

The request for a review should include your name and address for correspondence, the request for information to which the request relates and the issue which you wish to be reviewed. Please state the reference number **493-20** on this request. Your request should be made within 40 working days from receipt of this letter.

If following this review, you remain dissatisfied with the outcome, you may appeal to the Scottish Information Commissioner and request an investigation of your complaint. Your request to the Scottish Information Commissioner should be in writing (or other permanent form), stating your name and an address for correspondence. You should provide the details of the request and your reasons for dissatisfaction with both the original response by NHS Borders and your reasons for dissatisfaction with the outcome of the internal review. Your application for an investigation by the Scottish Information Commissioner must be made within six months of your receipt of the response with which you are dissatisfied. The address for the Office of the Scottish Information Commissioner is, Office of the Scottish Information Commissioner, Kinburn Castle, Doubledykes Road, St Andrews, Fife.